Janssen Research & Development LLC today announced data from a study published in The Lancet Oncology, evaluating the safety and activity of ibrutinib as a single-agent therapy in patients over the age of 65 with previously untreated chronic lymphocytic leukemia (CLL, N=29) or small lymphocytic lymphoma (SLL, N=2). Did the study meet its primary endpoint? Find out...
Seattle Genetics' Adcetris (brentuximab vedotin) antibody-drug conjugate has shown "compelling"...
New data analyses show that Boehringer-Ingelheim's Pradaxa was consistent in a wide...
Takeda today announced that a joint panel of members from the Gastrointestinal Drugs and Drug...
Daiichi Sankyo Co. Ltd. announced results of the Phase 3 Hokusai-VTE study, where patients with either a history of cancer or with active cancer treated with the once-daily factor Xa-inhibitor edoxaban had a lower incidence of recurrent symptomatic venous thromboembolism (VTE) compared to warfarin.
Adding bortezomib to standard preventive therapy for graft-versus-host-disease results in improved outcomes for patients receiving stem cell transplants from mismatched and unrelated donors, according to new research.
Researchers are one step closer to an eye drop-free reality with the development of a drug-eluting contact lens designed for prolonged delivery of latanoprost, a common drug used for the treatment of glaucoma.
Janssen Research & Development LLC today announced positive results from a pivotal Phase 2 global registration study suggesting siltuximab, an investigational compound, along with best supportive care (BSC), exhibited statistically significant efficacy and a tolerable safety profile. Read more...
Shares of Acura Pharmaceuticals Inc. rose Monday after the company said it met with federal regulators to discuss a new version of the painkiller hydrocodone that uses the company's abuse-resistant technology.
Janssen, the pharmaceutical companies of Johnson & Johnson, today announced a first-of-its-kind pediatric HIV treatment donation program to improve access to the company's approved HIV medicines for children and adolescents failing HIV treatment in sub-Saharan Africa.
Merck Serono announced that The Lancet Oncology has published results from the Phase 3 trial of its investigational MUC1 antigen specific cancer immunotherapy tecemotide in patients with unresectable, locally advanced Stage III non-small cell lung cancer, known as the START trial.
Princeton University has announced that a vaccination program with Novartis meningococcal serogroup B (MenB) vaccine, Bexsero (Meningococcal Group B Vaccine), began today following a campus outbreak that has affected at least eight students.
Millennium: The Takeda Oncology Co., together with Takeda Pharmaceutical Co. Ltd., announced results from a retrospective, subgroup analysis of the Phase 3 VISTA study that showed a higher cumulative dose of Velcade suggests improved overall survival in previously untreated patients with multiple myeloma.
U.S. health officials have approved a highly anticipated hepatitis C drug from Gilead Sciences Inc. that is expected to offer a faster, more palatable cure to millions of people infected with the liver-destroying virus.
GlaxoSmithKline and Theravance today announced positive results from a Phase 3 study of fluticasone furoate/vilanterol. So what do these additional data mean for a potential filing for an asthma indication for adults in the United States? Find out...
Novartis announced that results of a Phase 3 trial of LBH589 (panobinostat) in combination with bortezomib and dexamethasone, met the primary endpoint of significantly extending progression-free survival (PFS) in patients with multiple myeloma. Does the drug have the potential to be an important treatment option for multiple myeloma? Find out...
Shire plc announced top-line results from OPUS-2, a Phase 3 efficacy and safety study of 5% lifitegrast ophthalmic solution. Lifitegrast met the prespecified co-primary endpoint for the patient-reported symptom of eye dryness, but did not meet co-primary endpoint for the sign of inferior corneal staining score.
AstraZeneca today announced that the European Commission (EC) has granted Marketing Authorization to Fluenz Tetra. This makes Fluenz Tetra the first and only intra-nasal four-strain influenza vaccine available in Europe.
GSK announced that the European Commission has granted marketing authorization for an additional indication for Synflorix for the immunization against pneumonia caused by Streptococcus pneumonia in children from six weeks up to five years of age.
A study just published by the London Office of Health Economics (OHE) and its collaborators demonstrates how medicines for rare disease may be effectively valued using an innovative approach- multi-criteria decision analysis (MCDA)- that can include all relevant stakeholders, including patients' groups.
Hoffmann-La Roche Ltd. (Roche), in consultation with Health Canada, announced important new safety information regarding the use of Xeloda. Severe skin reactions have been reported in patients taking Xeloda.
Marinomed Biotechnologie GmbH announced that new clinical data confirmed the effectiveness of a Carragelose-based nasal spray in the therapy of common cold. The indicates regular use of the product can significantly reduces the duration of common cold symptoms.
Sanofi announced the results of a 24-week Phase 3b clinical study showing that Lyxumia met the primary endpoint of non-inferiority in blood sugar lowering when administered either before breakfast or the main meal of the day, indicate that lixisenatide works effectively at either time of administration.
Eli Lilly and Co. announced that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment. Lilly will not proceed with development of edivoxetine as an add-on treatment for depression.
Federal regulators gave the go-ahead to Arca Biopharma to begin human clinical testing of its treatment for atrial fibrillation, the company said Wednesday.
Immunomedics said Wednesday its cancer drug IMMU-132 will receive orphan drug incentives as a treatment for small cell lung cancer. The FDA awards orphan drug status to medications that are designed to treat diseases that affect fewer than 200,000 people in the U.S.
Cell Therapeutics Inc. announced that it concluded an agreement with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) in Germany for Pixuvri (pixantrone).
Medivation and Astellas Pharma US announced the initiation of a Phase 2 clinical trial evaluating the safety and efficacy of enzalutamide in combination with exemestane in women with advanced breast cancer that is ER+ or PgR+, and HER2 normal.
Teva and Takeda announced the signing of an agreement in which Teva licensed to Takeda the right to commercialize Teva’s innovative glatiramer acetate (active ingredient) formulation, for the treatment of multiple sclerosis, in Japan.
- Page 1